Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 433-460

  Feher, Victoria A ^a   Lawson, J David ^a  

^a Takeda San Diego Inc   (United States)

Author keywords

Accommodating active versus inactive kinase conformations; Kinase homology modeling approaches successes and considerations for structural kinome; Kinase homology modeling utilizing traditional modeling methods

Indexed keywords

EID: 84881420612     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch17     Document Type: Chapter

References (84)

1. Adrián, F. J., Ding, Q., Sim, T., et al. (2006). Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat Chem Biol. 2 (2), 95-102.
2. Altschul, S. F., Madden, T. L., Schäffer, A. A., et al. (1997). Gapped BLAST and PSI -BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (17), 3389-3402.
3. Arnold, L. D., Calderwood, D. J., Dixon, R. W., et al. (2000). Pyrrolo[2, 3-d ]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 10 (19), 2167-2170.
4. Atwell, S., Adams, J. M., Badger, J., et al. (2004). A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem. 279 (53), 55827-55832.
5. Bates, P. A., and Sternberg, M. J. (1999). Model building by comparison at CASP3: using expert knowledge and computer automation. Proteins Suppl. 3, 47-54.
6. Bates, P. A., Kelley, L. A., MacCallum, R. M., et al. (2001). Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins Suppl. 5, 39-46.
7. Berman, H. M., Westbrook, J., Feng, Z., et al. (2000). The Protein Data Bank. Nucleic Acids Res. 28 (1), 235-242.
8. Böhmer, F. D., Karagyozov, L., Uecker, A., et al. (2003). A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem. 278 (7), 5148-5155.
9. Breitenlechner, C., Gassel, M., Hidaka, H., et al. (2003). Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11 (12), 1595-1607.
10. Caldwell, J. J., Davies, T. G., Donald, A., et al. (2008). Identification of 4-(4-aminopiperidin-1-yl)-7 H-pyrrolo[2, 3-d ]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 51 (7), 2147-2157.
11. Canutescu, A. A., Shelenkov, A. A., and Dunbrack, R. L. (2003). A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 12 (9), 2001-2014.
12. Carlomagno, F., Guida, T., Anaganti, S., et al. (2004). Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 23 (36), 6056-6063.
13. Chemical Computing Group, MOE molecular modeling package. Available at http://www.chemcomp.com.
14. Cohen, P. (2002). Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov. 1 (4), 309-315.
15. Converso, A. (2008). Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. 236th ACS National Meeting, Philadelphia, PA.
16. Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16 (22), 10881-10890.
17. Davies, T. G., Verdonk, M. L., Graham, B., et al. (2007). A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol. 367 (3), 882-894.
18. Diller, D. J., and Li, R. (2003). Kinases, homology models, and high throughput docking. J Med Chem. 46 (22), 4638-4647.
19. Doolittle, R. (1986). Of Urfs and Orfs: A Primer on How to Analyze Derived Amino Acid Sequences. Sausalito, CA: University Science Books.
20. Dunbrack, R. L. (2006). Sequence comparison and protein structure prediction. Curr Opin Structural Biol. 16 (3), 374-384.
21. Fabian, M. A., Biggs, W. H., Treiber, D. K., et al. (2005). A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 23 (3), 329-336.
22. Fedorov, O., Sundström, M., Marsden, B., et al. (2007). Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discov. Today. 12 (9-10), 365-372.
23. Frye, S. V. (1999). Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem Biol. 6 (1), R3-7.
24. Ginalski, K. (2006). Comparative modeling for protein structure prediction. Curr Opin Structural Biol. 16 (2), 172-177.
25. Gridelli, C., Maione, P., and Rossi, A. (2008). The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 13 (2), 139-147.
26. Hanks, S. K., and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (8), 576-596.
27. Hanks, S. K., and Quinn, A. M. (1991). Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. In: B. M. Sefton and T. Hunter (eds.), Methods in Enzymology, Vol. 200, pp. 38-62. Hoboken, NJ: Wiley.
28. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241 (4861), 42-52.
29. Heron, N. M., Anderson, M., Blowers, D. P., et al. (2006). SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg Med Chem Lett. 16 (5), 1320-1323.
30. Honma, T., Hayashi, K., et al. (2001a). Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 44 (26), 4615-4627.
31. Honma, T., Yoshizumi, T., et al. (2001b). A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem. 44 (26), 4628-4640.
32. Ikuta, M., Kamata, K., Fukasawa, K., et al. (2001). Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J Biol Chem. 276 (29), 27548-27554.
33. Iwakubo, M., Takami, A., Okada, Y., et al. (2007a). Design and synthesis of Rho kinase inhibitors (II). Bioorg Med Chem. 15 (1), 350-364.
34. Iwakubo, M., Takami, A., Okada, Y., et al. (2007b). Design and synthesis of rho kinase inhibitors (III). Bioorg Med Chem. 15 (2), 1022-1033.
35. Jacobs, M. D., Caron, P. R., and Hare, B. J. (2008). Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins. 70 (4), 1451-1460.
36. Jelić, D., Mildner, B., Kostrun, S., et al. (2007). Homology modeling of human Fyn kinase structure: discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes. J Med Chem. 50 (6), 1090-1100.
37. Johnson, D. A., Akamine, P., Radzio-Andzelm, E., et al. (2001). Dynamics of cAMP -dependent protein kinase. Chem Rev. 101 (8), 2243-2270.
38. Kinoshita, T., Matsubara, M., Ishiguro, H., et al. (2006). Structure of human Fyn kinase domain complexed with staurosporine. Biochem Biophys Res Commun. 346 (3), 840-844.
39. Larkin, M. A., Blackshields, G., Brown, N. P., et al. (2007). Clustal W and Clustal X version 2.0. Bioinformatics (Oxford, England), 23 (21), 2947-2948.
40. Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., et al. (1996). AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 8 (4), 477-486.
41. Li, W., Jaroszewski, L., and Godzik, A. (2002). Sequence clustering strategies improve remote homology recognitions while reducing search times. Protein Eng. 15 (8), 643-649.
42. Lu, B., Wong, C. F., and McCammon, J. A. (2005). Release of ADP from the catalytic subunit of protein kinase A: a molecular dynamics simulation study. Protein Sci. 14 (1), 159-168.
43. Madhusudhan, M. S., Marti-Renom, M. A., Eswar, N., et al. (2005). Comparative protein structure modeling. In: J. M. Walker (ed.), The Proteomics Protocols Handbook. Totowa, NJ: Humana Press, p. 1016.
44. Manning, G., Whyte, D. B., Martinez, R., et al. (2002). The protein kinase complement of the human genome. Science. 298 (5600), 1912-1934.
45. Marsden, B. D., and Knapp, S. (2008). Doing more than just the structure-structural genomics in kinase drug discovery. Curr Opin Chem Biol. 12 (1), 40-45.
46. Martí-Renom, M. A., Stuart, A. C., Fiser, A., et al. (2000). Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Structure. 29, 291-325.
47. Mavrou, A., Tsangaris, G. T., Roma, E., et al. (2008). The ATM gene and ataxia telangiectasia. Anticancer Res. 28 (1B), 401-405.
48. McInnes, C., Wang, S., Anderson, S., et al. (2004). Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 11 (4), 525-534.
49. McInnes, C., Mezna, M., and Fischer, P. M. (2005). Progress in the discovery of polo -like kinase inhibitors. Curr Top Med Chem. 5 (2), 181-197.
50. Mol, C. D., Dougan, D. R., Schneider, T. R., et al. (2004). Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 279 (30), 31655-31663.
51. Molsoft L. L. C., ICM-Homology Module. Available at http://www.molsoft.com/.
52. Mori, Y., Hirokawa, T., Aoki, K., et al. (2008). Structure-activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor beta receptor (PDGFR β) inhibitors, derived from molecular modeling. Chem Pharm Bull. 56, 682-687.
53. Nagar, B., Bornmann, W. G., Pellicena, P., et al. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (15), 4236-4243.
54. Nayeem, A., Sitkoff, D., and Krystek, S. (2006). A comparative study of available software for high-accuracy homology modeling: from sequence alignments to structural models. Protein Sci. 15 (4), 808-824.
55. Noble, M. E. M., Endicott, J. A., and Johnson, L. N. (2004). Protein kinase inhibitors: insights into drug design from structure. Science. 303 (5665), 1800-1805.
56. Ohren, J. F., Chen, H., Pavlovsky, A., et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Structural Mol Biol. 11 (12), 1192-1197.
57. Omura, S., Iwai, Y., Hirano, A., et al. (1977). A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiotics. 30 (4), 275-282.
58. Orengo, C. A., and Thornton, J. M. (2005). Protein families and their evolution-a structural perspective. Annu Rev Biochem. 74, 867-900.
59. Pan, Z., Scheerens, H., Li, S., et al. (2007). Discovery of selective irreversible inhibitors for Bruton ' s tyrosine kinase. ChemMedChem. 2 (1), 58-61.
60. Petrey, D., Xiang, Z., Tang, C. L., et al. (2003). Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins. 53 (Suppl 6), 430-435.
61. Pratt, D. J., Bentley, J., Jewsbury, P., et al. (2006). Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 49 (18), 5470-5477.
62. Rockey, W. M., and Elcock, A. H. (2006). Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? Curr Protein Peptide Sci. 7 (5), 437-457.
63. Sali, A., and Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 234 (3), 779-815.
64. Sandberg, E. M., Ma, X., He, K., et al. (2005). Identification of 1, 2, 3, 4, 5, 6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation ]. J Med Chem. 48 (7), 2526-2533.
65. Seeliger, M. A., Nagar, B., Frank, F., et al. (2007). c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure. 15 (3), 299-311.
66. Smith, S. M. (2007). Clinical development of mTOR inhibitors: a focus on lymphoma. Rev Recent Clin Trials. 2 (2), 103-110.
67. Sutcliffe, M. J., Haneef, I., Carney, D., et al. (1987). Knowledge based modelling of homologous proteins, Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures. Protein Eng. 1 (5), 377-384.
68. Takami, A., Iwakubo, M., Okada, Y., et al. (2004). Design and synthesis of Rho kinase inhibitors (I). Bioorg Med Chem. 12 (9), 2115-2137.
69. Taylor, S. S. (1989). cAMP-dependent protein kinase. Model for an enzyme family. J Biol Chem. 264 (15), 8443-8446.
70. Taylor, S. S., Kim, C., Vigil, D., et al. (2005). Dynamics of signaling by PKA. Biochim Biophys Acta. 1754 (1-2), 25-37.
71. Tobak, A. T. (2007). Construction of the 3D structure of the mTOR kinase-domain and discovery of novel mTOR inhibitors. PhD thesis, Rutgers University.
72. Tripos, Inc., SYBYL molecular modeling package. Available at http://www.tripos.com.
73. Tsou, H., Otteng, M., Tran, T., et al. (2008). 4-(Phenylaminomethylene)isoquinoline -1, 3(2H, 4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). J Med Chem. 51 (12), 3507-3525.
74. Tuccinardi, T., Manetti, F., Schenone, S., et al. (2007). Construction and validation of a RET TK catalytic domain by homology modeling. J Chem Inf Modeling. 47 (2), 644-655.
75. UniProt Consortium (2008). The universal protein resource (UniProt). Nucleic Acids Res. 36 (Database issue), D190-195.
76. Vangrevelinghe, E., Zimmermann, K., Schoepfer, J., et al. (2003). Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J Med Chem. 46 (13), 2656-2662.
77. Verma, S., Nagarathnam, D., Shao, J., et al. (2005). Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 15 (8), 1973-1977.
78. Vieth, M., Sutherland, J. J., Robertson, D. H., et al. (2005). Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today. 10 (12), 839-846.
79. Vriend, G. (1990). WHAT IF: a molecular modeling and drug design program. J Mol Graphics. 8 (1), 52-56, 29.
80. Walker, E. H., Pacold, M. E., Perisic, O., et al. (2000). Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 6 (4), 909-919.
81. Wang, S., Meades, C., Wood, G., et al. (2004). 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem. 47 (7), 1662-1675.
82. Xiang, Z. (2006). Advances in homology protein structure modeling. Curr Protein Peptide Sci. 7 (3), 217-227.
83. Yount, R. G., Babcock, D., Ballantyne, W., et al. (1971). Adenylyl imidodiphosphate, an adenosine triphosphate analog containing a P-N-P linkage. Biochemistry. 10 (13), 2484-2489.
84. Zheng, J., Trafny, E. A., Knighton, D. R., et al. (1993). 2.2 Årefined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr D. Biol. 49 (Pt 3), 362-365.